AKT1 and prostate carcinoma: In addition, activation of the EGFR/MAPK/mTOR/AKT/ERK1/2 signaling pathway in various cancers, such as glioblastoma, endometrial cancer, and prostate cancer can promote cancer cell invasion, metastasis, and drug resistance.